Your trusted source for GLP-1 research, news, and patient insights.
10 posts in this category
MariTide is an experimental once-monthly weight-loss shot in Phase 3. See how it works, what trials showed, and how it compares to weekly shots.
The FDA moved 12 peptides off its restricted list and reviews 7 in July 2026. See what it could mean for compounding, your GLP-1, and peptide safety.
Retatrutide is not FDA approved, but some clinics sell it anyway. See what the science shows and why approval status matters for you.
New 2026 genetics research explains why GLP-1s work better for some people than others, plus what to do if your response feels slower than expected.
Products marketed as "natural GLP-1s" and peptide supplements are everywhere. Here is what the science says and how to protect yourself.
Major GLP-1 and obesity drug trials are finishing in 2027. Here’s what they’re studying and what it could mean for access and affordability.
Peer-reviewed research shows GLP-1 medications do not meaningfully increase cancer risk. Here’s what large human studies say in 2026.
Learn what orforglipron is, how this daily oral GLP-1 works, where the research stands now, and what to watch for as it moves toward FDA review.
Learn how FDA-approved GLP-1 medications like Wegovy, Ozempic, Mounjaro, and Zepbound work—and what to know about compounded and next-gen options.
Learn what microdosing GLP-1s really means, what’s known, what’s not, and key questions to ask your doctor before considering it.
